Key result
Nanoparticle co-delivery of quercetin and doxorubicin cuts in vitro cardiotoxicity ~50% in cardioblasts.
Why the study?
Doxorubicin's cardiotoxicity and hydrophilicity limit its therapeutic use, and co-delivery with quercetin may reduce cardiotoxicity with sustained release.
Double loading of doxorubicin and quercetin in carboxy-modified MCM-41 nanoparticles decreases in vitro cardiotoxicity in H9c2 cells, offering a potential chemotherapeutic formulation.
Answers are grounded in this paper and cite their sources.
Supports preclinical testing of dual-loaded MCM-41 nanoparticles; leaves open in vivo efficacy and clinical translation.
Background: One of the therapeutic limitations of the use of doxorubicin (DOX) as an anticancer drug is its cardiotoxicity. Its hydrophilicity also causes difficulties in achieving sustained release. The simultaneous delivery with the well-known natural antioxidant quercetin could ameliorate its cardiotoxicity. Thus, the main aim of this work is to study the potential of carboxylated and non-carboxylated mesoporous silica MCM-41 nanoparticles for double loading of the hydrophilic doxorubicin hydrochloride and hydrophobic quercetin (Q) in one nanocarrier with a modified release pattern to reduce the cardiotoxic side effects of doxorubicin in vitro. Methods: The methods included the modification of MCM-41, single and double loading of modified and non-modified MCM-41, physicochemical characterization, in vitro release tests and kinetic study, and in vitro cell viability studies. Results: Doxorubicin and quercetin were successfully double-loaded with encapsulation efficiency (EE) of 43 ± 4.1% and 37 ± 4.5%, respectively, in native MCM-41. The post-synthetic carboxylation led to 49 ± 4.3% EE (DOX) and 36 ± 4.0% (Q) and double lowering of the cardiotoxicity on H9c2 (IC50 = 5.96 µm). Sustained release profiles over 72 h were achieved. Conclusions: A successful procedure was proposed for the efficient double loading of a hydrophilic drug and a hydrophobic drug. The carboxy-modified double-loaded nanosystems demonstrate a decreased in vitro cardiotoxicity of doxorubicin and can be considered as a potential chemotherapeutic formulation.
No takes yet. Share an insight, caveat, or question.
Voycheva et al. (2023) studied Doxorubicin-induced cardiotoxicity. Doxorubicin and quercetin double-loaded in carboxy-modified MCM-41 nanoparticles vs. Free doxorubicin was evaluated on In vitro cardiotoxicity (IC50) on H9c2 cells (IC50 = 5.96 µm). Carboxy-modified MCM-41 nanoparticles double-loaded with doxorubicin and quercetin halved the in vitro cardiotoxicity of doxorubicin on H9c2 cardioblast cells, achieving an IC50 of 5.96 µm.
Synapse has enriched 10 related papers. Consider them for comparative context: